Abstract
Gemcitabine has recently been compared favorably to 5-fluorouracil (5-FU) as the standard chemotherapy for advanced pancreas cancer. Based on phase I data that combining gemcitabine with 5-FU is safe and has evidence for clinical activity, a phase II trial was conducted by the Eastern Cooperative Oncology Group (ECOG). Patients with metastatic disease, good performance status and organ function were eligible and enrolled after providing informed consent. Patients were given gemcitabine (1000 mg/m2) followed by 5-FU (600 mg/m2) weekly for 3 weeks of every 4. Of 37 patients enrolled over a 3-month period, 36 were eligible. Partial responses were seen in 5 patients (14%), Median survival was 4.4 months with a 1-year survival rate of 8.6%, A randomized trial of the combination of 5-FU and gemcitabine versus gemcitabine alone is currently accruing patients in ECOG. Copyright (C) 2000 S. Karger AG, Basel.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 215-218 |
| Number of pages | 4 |
| Journal | Oncology |
| Volume | 58 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jan 1 2000 |
Fingerprint
Keywords
- 5-Fluorouracil
- Gemcitabine
- Pancreas cancer
- Phase II trial
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
}
A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer : An Eastern Cooperative Oncology Group study (E3296). / Berlin, Jordan D.; Adak, Sudeshna; Vaughn, David J.; Flinker, David; Blaszkowsky, Lawrence; Harris, Jules E.; Benson III, Al B.
In: Oncology, Vol. 58, No. 3, 01.01.2000, p. 215-218.Research output: Contribution to journal › Article
TY - JOUR
T1 - A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer
T2 - An Eastern Cooperative Oncology Group study (E3296)
AU - Berlin, Jordan D.
AU - Adak, Sudeshna
AU - Vaughn, David J.
AU - Flinker, David
AU - Blaszkowsky, Lawrence
AU - Harris, Jules E.
AU - Benson III, Al B
PY - 2000/1/1
Y1 - 2000/1/1
N2 - Gemcitabine has recently been compared favorably to 5-fluorouracil (5-FU) as the standard chemotherapy for advanced pancreas cancer. Based on phase I data that combining gemcitabine with 5-FU is safe and has evidence for clinical activity, a phase II trial was conducted by the Eastern Cooperative Oncology Group (ECOG). Patients with metastatic disease, good performance status and organ function were eligible and enrolled after providing informed consent. Patients were given gemcitabine (1000 mg/m2) followed by 5-FU (600 mg/m2) weekly for 3 weeks of every 4. Of 37 patients enrolled over a 3-month period, 36 were eligible. Partial responses were seen in 5 patients (14%), Median survival was 4.4 months with a 1-year survival rate of 8.6%, A randomized trial of the combination of 5-FU and gemcitabine versus gemcitabine alone is currently accruing patients in ECOG. Copyright (C) 2000 S. Karger AG, Basel.
AB - Gemcitabine has recently been compared favorably to 5-fluorouracil (5-FU) as the standard chemotherapy for advanced pancreas cancer. Based on phase I data that combining gemcitabine with 5-FU is safe and has evidence for clinical activity, a phase II trial was conducted by the Eastern Cooperative Oncology Group (ECOG). Patients with metastatic disease, good performance status and organ function were eligible and enrolled after providing informed consent. Patients were given gemcitabine (1000 mg/m2) followed by 5-FU (600 mg/m2) weekly for 3 weeks of every 4. Of 37 patients enrolled over a 3-month period, 36 were eligible. Partial responses were seen in 5 patients (14%), Median survival was 4.4 months with a 1-year survival rate of 8.6%, A randomized trial of the combination of 5-FU and gemcitabine versus gemcitabine alone is currently accruing patients in ECOG. Copyright (C) 2000 S. Karger AG, Basel.
KW - 5-Fluorouracil
KW - Gemcitabine
KW - Pancreas cancer
KW - Phase II trial
UR - http://www.scopus.com/inward/record.url?scp=0034029777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034029777&partnerID=8YFLogxK
U2 - 10.1159/000012103
DO - 10.1159/000012103
M3 - Article
C2 - 10765123
AN - SCOPUS:0034029777
VL - 58
SP - 215
EP - 218
JO - Oncology
JF - Oncology
SN - 0890-9091
IS - 3
ER -